Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial

BACKGROUND: Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually relieve the severity of symptoms by as much as 20–30%, and satisfactory treatment is obtained in 40–60% of patients with OCD. Nevertheless, the remaining symptoms continue to impair the pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghobadian, Ala, Mokhtari, Saba, Shariati, Behnam, Kamalzadeh, Leila, Shati, Mohsen, Eftekhar Ardebili, Mehrdad, Yarahmadi, Masoomeh, Shalbafan, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516841/
https://www.ncbi.nlm.nih.gov/pubmed/36167636
http://dx.doi.org/10.1186/s40360-022-00610-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516841/
https://www.ncbi.nlm.nih.gov/pubmed/36167636
http://dx.doi.org/10.1186/s40360-022-00610-5

Ejemplares similares